Stockscreener 앱 받기
29.34
5.05%
1.41
전일 마감가:
$27.93
열려 있는:
$27.82
하루 거래량:
1.07M
Relative Volume:
0.92
시가총액:
$1.68B
수익:
$199.89M
순이익/손실:
$52.48M
주가수익비율:
34.52
EPS:
0.85
순현금흐름:
$61.15M
1주 성능:
+10.68%
1개월 성능:
-15.40%
6개월 성능:
+209.49%
1년 성능:
+160.34%
1일 변동 폭
$27.53
$29.46
1주일 범위
$25.31
$29.46
52주 변동 폭
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
29.34 | 1.60B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Stoke Therapeutics Target of Unusually High Options Trading (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
(STOK) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Why Stoke Therapeutics Inc. stock remains undervaluedMarket Risk Report & Short-Term High Return Ideas - newser.com
Can Stoke Therapeutics Inc. stock sustain institutional interest2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
How Stoke Therapeutics Inc. stock valuations compare to rivalsProduct Launch & Verified Momentum Stock Alerts - newser.com
Can Stoke Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Report & High Conviction Buy Zone Alerts - newser.com
Can Stoke Therapeutics Inc. stock resist sector downturns2025 Top Decliners & Intraday High Probability Alerts - newser.com
Stoke Therapeutics (NASDAQ:STOK) Director Adrian Krainer Sells 40,472 Shares - MarketBeat
Does Stoke Therapeutics Inc. show high probability of reboundJuly 2025 Gainers & Weekly High Return Forecasts - newser.com
Is Stoke Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Weekly High Conviction Ideas - newser.com
Live market analysis of Stoke Therapeutics Inc.July 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Why Stoke Therapeutics Inc. stock attracts high net worth investorsBear Alert & Fast Moving Stock Trade Plans - newser.com
Stoke Therapeutics (NASDAQ:STOK) Trading Up 7.6%Still a Buy? - MarketBeat
Will Stoke Therapeutics Inc. stock maintain momentum in 20252025 Analyst Calls & Risk Managed Investment Signals - newser.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
19,300 Shares in Stoke Therapeutics, Inc. $STOK Purchased by Integrated Quantitative Investments LLC - MarketBeat
Los Angeles Capital Management LLC Makes New $224,000 Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)November 18, 2025 - BioSpace
What technical models suggest about Stoke Therapeutics Inc.’s comeback2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Director Adrian R. Krainer Sells Over 40,000 Shares - TradingView
Dir Krainer Sells 40,472 ($1.1M) Of Stoke Therapeutics Inc [STOK] - TradingView
[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan
Could Endpoint Choices in the EMPEROR Trial Reveal a Strategic Shift for Stoke Therapeutics (STOK)? - simplywall.st
Biogen (BIIB) and Stoke Release Results from Dravet Syndrome Stu - GuruFocus
Biogen (BIIB) Reveals Key Findings from Dravet Syndrome Study - GuruFocus
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - The Manila Times
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Business Wire
Exit strategy if you’re trapped in Stoke Therapeutics Inc.July 2025 Action & Fast Momentum Stock Entry Tips - newser.com
Using portfolio simulators with Stoke Therapeutics Inc. includedJuly 2025 PostEarnings & Verified Chart Pattern Signals - newser.com
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):